The FDA halted the use of two monoclonal antibody treatments for COVID-19 because they are not effective against the omicron variant of SARS-CoV-2, which now accounts for almost all U.S. cases. The FDA revised the emergency use authorizations for the two treatments bamlanivimab and etesevimab administered together, and the cocktail of casirivimab and imdevimab. Their use will now be limited to
Less than optimal heart health at midlife was associated with a decline in the mental processing speed of Black women, but not white women, researchers…
ATLANTA — Adults genetically predisposed to high stress are more likely to have a heart attack during times of heightened stress, such as a major…
Endoscopic sleeve gastroplasty was more cost-effective and sustained greater weight loss over 5 years compared with semaglutide for patients with class II obesity, according to…
Websites focused on inhaler technique frequently overlook important preparation steps and device care/maintenance, according to results published in Respiratory Medicine.These findings emphasize the importance of…
Implementing the recent stronger standard for fine particulate pollution revealed that 131 million Americans breathe unhealthy, polluted air where they live, according to a press…
Patients in rheumatoid arthritis remission who tapered off conventional synthetic disease-modifying antirheumatic drugs had higher risks for flares, with two methods failing to reach non-inferiority…
Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic…
SAN DIEGO — Researchers have developed a new tool to assess malnutrition in children with end-stage kidney disease to help prevent protein-energy wasting, according…
BOSTON — In this Healio Video Perspective from the ASCRS meeting, Alice T. Epitropoulos, MD, FACS, discusses Vevye, a cyclosporine solution that treats signs and…
In a 3-2 vote, the Federal Trade Commission passed a final rule that bans new noncompete agreements with all workers in for-profit organizations. For existing…
